Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis

13Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues.

Cite

CITATION STYLE

APA

Morris, A. H., Hughes, K. R., Oakes, R. S., Cai, M. M., Miller, S. D., Irani, D. N., & Shea, L. D. (2020). Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-17629-z

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free